IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. Its outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. The company operates 16 outpatient clinics in Kentucky, Missouri, Tennessee, Illinois, and Florida. IMAC Holdings, Inc. was founded in 2000 and is based in Brentwood, Tennessee.
IPO Year: 2019
Exchange: NASDAQ
Website: imacregeneration.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/19/2021 | $2.35 → $1.75 | Buy → Neutral | National Alliance Securities |
BRENTWOOD, Tenn., Jan. 07, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces the appointment of Sheri Gardzina, CPA as its Chief Financial Officer. To date, Ms. Gardzina has served as CFO in an interim capacity. “Sheri has been an excellent addition to our management team since joining the company and we are pleased to have her as our permanent Chief Financial Officer. She brings a wealth of financial and accounting experience to the company and I am excited to continue worki
4 - IMAC Holdings, Inc. (0001729944) (Issuer)
4 - IMAC Holdings, Inc. (0001729944) (Issuer)
4 - IMAC Holdings, Inc. (0001729944) (Issuer)
4 - IMAC Holdings, Inc. (0001729944) (Issuer)
4 - IMAC Holdings, Inc. (0001729944) (Issuer)
4 - IMAC Holdings, Inc. (0001729944) (Issuer)
3 - IMAC Holdings, Inc. (0001729944) (Issuer)
4 - IMAC Holdings, Inc. (0001729944) (Issuer)
4 - IMAC Holdings, Inc. (0001729944) (Issuer)
4 - IMAC Holdings, Inc. (0001729944) (Issuer)
National Alliance Securities downgraded IMAC Holdings from Buy to Neutral and set a new price target of $1.75 from $2.35 previously
SC 13G - IMAC Holdings, Inc. (0001729944) (Subject)
SC 13G/A - IMAC Holdings, Inc. (0001729944) (Subject)
SC 13G - IMAC Holdings, Inc. (0001729944) (Subject)
SC 13G/A - IMAC Holdings, Inc. (0001729944) (Subject)
SC 13G/A - IMAC Holdings, Inc. (0001729944) (Subject)
SC 13G - IMAC Holdings, Inc. (0001729944) (Subject)
SC 13G - IMAC Holdings, Inc. (0001729944) (Subject)
BRENTWOOD, Tenn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:IMAC) ("IMAC" or the "Company"), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces financial results for the third quarter ended September 30, 2021. Financial Highlights from 3Q 2021 (all comparisons are with the quarter ended September 30, 2020, unless otherwise indicated): Total revenue was $3.49 million, compared with $3.48 millionTotal patient visits at IMAC Centers were up 10% to 43,451, compared to 39,345Net loss was $1.7 million, or a loss of $0.07 per share, compared with a net
IMAC reports 36% increase in revenues and 70% increase in patient visits as it invests in value-generating assets BRENTWOOD, Tenn., Aug. 12, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:IMAC) ("IMAC" or the "Company"), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces financial results for the second quarter ended June 30, 2021. Financial Highlights from 2Q 2021 (all comparisons are for the quarter ended June 30, 2020, unless otherwise indicated): Total revenue was $3.4 million, compared with $2.5 million, an increase o
Naperville, Ill. purchase to be rebranded Mike Ditka IMAC Regeneration Center BRENTWOOD, Tenn., June 25, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) ("IMAC" or the "Company"), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, announces the Company's expansion in the Chicago market with the asset purchase of Active Medical Center's Naperville, Illinois location, effective Monday, June 28. Active Medical Center is a medical clinic that addresses a wide variety of orthopedic treatments for various conditions through a combination of medical and physical rehabilitatio
Purchase Marks Third Florida Acquisition this Year BRENTWOOD, Tenn, June 14, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) ("IMAC" or the "Company"), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, announces its purchase of Fort Pierce Chiropractic effective today. "Award-winning Fort Pierce Chiropractic has been a staple to the Treasure Coast community along Highway 1 for over 30 years. We anticipate building upon the historical success of this practice by introducing medical services to the current patient base receiving excellent spinal care from the ex
IMAC Holdings, Inc. (Nasdaq: IMAC) ("IMAC" or the "Company"), will change its ticker symbol on the NASDAQ Stock Exchange from "IMAC" to "BACK" at the open of market trading on Monday, August 8, 2022.
Gainers Allarity Therapeutics (NASDAQ:ALLR) stock rose 16.4% to $1.42 during Tuesday's pre-market session. The company's market cap stands at $13.1 million. Vaccinex (NASDAQ:VCNX) stock rose 12.91% to $1.15. The company's market cap stands at $49.1 million. Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 12.49% to $4.05. The market value of their outstanding shares is at $38.0 million. Harmony Biosciences (NASDAQ:HRMY) shares moved upwards by 10.25% to $54.28. The market value of their outstanding shares is at $3.2 billion. As per the news, the Q2 earnings report came out today. Sonnet BioTherapeutics (NASDAQ:SONN) shares increased by 9.84% to $0.3. The company's market ca
Gainers Dave Inc. (NASDAQ:DAVE) rose 56.9% to $0.9826 in pre-market trading. Dave is expected to release its second quarter 2022 financial results on Thursday, August 11, 2022. Pzena Investment Management, Inc (NYSE:PZN) rose 46.4% to $9.43 in pre-market trading as the company said it has entered into an agreement to become a private company. The company also reported a rise quarterly sales. Teva Pharmaceutical Industries Limited (NYSE:TEVA) rose 18.3% to $8.42 in pre-market trading after the company reported better-than-expected financial results. Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) rose 18.1% to $0.31 in pre-market trading after declining more than 9% on Tuesday. AI
IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced that its board of directors has initiated an exploration of strategic alternatives. As part of this process, the board will consider a wide range of options for the company including, among other things, a potential merger, spin-off, sale, or other strategic transaction for one or more of its key business units or assets. “As our company continues to expand into complementary revenue streams, we believe the time is right to investigate a range of strategic
Gainers Addex Therapeutics (NASDAQ:ADXN) shares increased by 46.1% to $1.34 during Thursday's pre-market session. The company's market cap stands at $8.4 million. Tabula Rasa HealthCare (NASDAQ:TRHC) stock moved upwards by 14.61% to $2.98. The company's market cap stands at $77.0 million. MoonLake (NASDAQ:MLTX) stock rose 14.1% to $6.31. The market value of their outstanding shares is at $233.0 million. SELLAS Life Sciences Gr (NASDAQ:SLS) shares increased by 13.17% to $2.92. The market value of their outstanding shares is at $59.9 million. Olema Pharmaceuticals (NASDAQ:OLMA) shares increased by 10.4% to $5.2. The company's market cap stands at $209.8 million. Endo International (
IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), today announces significant traffic growth for The Back Company. The Back Space retail chiropractic centers, located in select Walmart stores, generated over 100% visit growth compared to the first quarter. “Our team’s effort is evident as we continue to improve systems to support our doctors that delivered over 6,500 visits this calendar quarter,” said Jeff Ervin, Chief Executive Officer of IMAC. “The Back Space growth for the second quarter will be a springboard to material revenue during the second half of the year. This growth is significant since we just celebrated our first birthday as a concept and many of our stores opene
BRENTWOOD, Tenn., June 15, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), today announces the launch of retail healthcare products for optimal spinal health and wellness for IMAC patients.
10-Q - IMAC Holdings, Inc. (0001729944) (Filer)
EFFECT - IMAC Holdings, Inc. (0001729944) (Filer)
S-3/A - IMAC Holdings, Inc. (0001729944) (Filer)
S-3 - IMAC Holdings, Inc. (0001729944) (Filer)
8-K - IMAC Holdings, Inc. (0001729944) (Filer)
D - IMAC Holdings, Inc. (0001729944) (Filer)
10-Q - IMAC Holdings, Inc. (0001729944) (Filer)
8-K - IMAC Holdings, Inc. (0001729944) (Filer)
424B5 - IMAC Holdings, Inc. (0001729944) (Filer)
8-K - IMAC Holdings, Inc. (0001729944) (Filer)
BRENTWOOD, Tenn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) ("IMAC" or the "Company"), will change its ticker symbol on the NASDAQ Stock Exchange from "IMAC" to "BACK" at the open of market trading on Monday, August 8, 2022. "IMAC Holdings has developed a continuum of care for optimal spinal health, from the chiropractic wellness centers at the BackSpace to the IMAC Regeneration Centers' medical doctors, nurse practitioners, and physical therapists delivering advanced and innovative medical intervention," said Jeffrey Ervin, IMAC's Chief Executive Officer. "The spine is your body's central support structure and we recognize its importance for your overall health
BRENTWOOD, Tenn., July 26, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) ("IMAC" or the "Company"), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced that its board of directors has initiated an exploration of strategic alternatives. As part of this process, the board will consider a wide range of options for the company including, among other things, a potential merger, spin-off, sale, or other strategic transaction for one or more of its key business units or assets. "As our company continues to expand into complementary revenue streams, we believe
The Back Space sequential quarter traffic increased over 100% BRENTWOOD, Tenn., June 30, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) ("IMAC" or the "Company"), today announces significant traffic growth for The Back Company. The Back Space retail chiropractic centers, located in select Walmart stores, generated over 100% visit growth compared to the first quarter. "Our team's effort is evident as we continue to improve systems to support our doctors that delivered over 6,500 visits this calendar quarter," said Jeff Ervin, Chief Executive Officer of IMAC. "The Back Space growth for the second quarter will be a springboard to material revenue during the second half of the y
BRENTWOOD, Tenn., May 13, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) ("IMAC" or the "Company"), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today reported its preliminary financial results for the first quarter ended March 31, 2022. Financial and Corporate Highlights from Q1 2022: Total Revenue was $3.9 million, compared with $3.0 million in Q1 2021, an increase of 28%Patient visits were up 3.7% to 39,809 in IMAC clinicsCompleted repayment of three loans of over $4.34 million, which represented more than 95% of the company's debtSuccessfully completed i
BRENTWOOD, Tenn., April 29, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) ("IMAC" or the "Company"), today announces the selection of two The Back Space locations in the Orlando metropolitan area. After the successful completion of its pilot program for The Back Space retail chiropractic concept located in select Walmart stores, the Company is capitalizing on consumer acceptance in the central Florida test market by adding locations in Orlando and Sanford. "We are excited about the progress of the Back Space and recognize there is an opportunity to develop brand awareness and operating efficiencies with more storefronts to piggyback early success in our central Florida test
The Company plans to add 20 locations in the next 12 months BRENTWOOD, Tenn., April 07, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) ("IMAC" or the "Company"), today announces the successful completion of its pilot program for The Back Space retail chiropractic concept located in select Walmart stores. As a result, the Company is committed to tripling its store count with at least 20 additional locations over the next twelve months with a further goal of adding significantly more stores over the next three years. The Company expects the new stores to be a combination of corporate and The Back Company franchise locations to address market demand. "We are excited to guide o
Revenue increased 26% for quarter and 12% annually BRENTWOOD, Tenn., March 31, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) ("IMAC" or the "Company"), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today reported its preliminary financial results for the year ended December 31, 2021. Financial Highlights from Q4 2021: $4,368,564 in revenue in Q4 21, up 26% from Q4 20 revenue of $3,463,221IMAC Regeneration Center total visits for Q4 21 were 41,898, up 9.7% from 38,205 during Q4 20 Financial Highlights from FY 2021 (all comparisons are with IMAC for the
BRENTWOOD, Tenn, March 24, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) ("IMAC" or "the Company"), today announces it has initiated the third and final cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson's disease. About IMAC's Phase 1 Clinical Trial The Phase 1 clinical trial, consisting of a 15-patient dose escalation safety and tolerability study, is being conducted at IMAC Regeneration Centers in Chesterfield, Missouri, Paducah, Kentucky, and Brentwood, Tennessee. The trial is divided into three groups: 1) five patients with bradykinesi
Expansion plan leverages Walmart pilot to meet growing demand for spinal health and wellness BRENTWOOD, Tenn., March 15, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) ("IMAC" or the "Company") today announces it completed Franchise Disclosure Documents to launch The Back Company franchise spinal health and wellness centers. Capitalizing on the launch of the Company's Back Space concept, piloted in select Walmart locations, IMAC will launch The Back Company franchise April 1st. The Back Company specializes in chiropractic adjustments, corrective instrument adjusting, and percussion therapies for soft tissue recovery, muscle relaxation, and spinal wellness. Servic
BRENTWOOD, Tenn., Feb. 16, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:IMAC) ("IMAC" or "the Company"), today announces it has completed the second cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson's disease. The second cohort consists of five patients with bradykinesia due to Parkinson's disease receiving an intravenous infusion of a medium concentration stem cell treatment. The cohort was completed on Tuesday, February 15, 2022. In accordance with the trial protocol, the Company will wait at least 30 days to demonstrate safety of the medium co